Apoquel
Veterinary dermatology medicine
1 conceptApoquel is Zoetis's oclacitinib-based prescription product family for allergic itch and atopic dermatitis in dogs at least 12 months old.
ProductsZoetis
Zoetis product analyses
A tighter look at the products that matter most to Zoetis, along with the free, open, decentralized, or cooperative alternatives already creating pricing pressure and the original disruption concepts that could widen that pressure further.
Products
Where the moat actually touches users
These pages zoom into the products and services that matter most to each company, the alternatives already nibbling at them, and 2 structured disruption concepts across the current product set.
2 disruption concepts tracked0 documented exceptions
Simparica Trio
Companion animal parasiticide
1 conceptSimparica Trio is a monthly prescription chewable for dogs that combines protection against heartworm disease, fleas, multiple tick species, roundworms, hookworms, and flea tapeworm risk via flea control.
Paper trail
Company-level source stack
These sources shaped the scoring and writing. The site is opinionated, but it should not behave like it is improvising facts in a dark room.
Zoetis 2025 Form 10-K
U.S. Securities and Exchange Commission · annual report
Primary filing for 2025 revenue, net income, segment mix, product-category revenue, channel risks, and regulated manufacturing context.
Reviewed 2026-06-27
Zoetis Investor Relations Corporate Overview
Zoetis · investor relations
Company overview describing Zoetis as an animal-health company with medicines, vaccines, diagnostics, biopharmaceuticals, and digital solutions across more than 100 countries.
Reviewed 2026-06-27
Zoetis Market Capitalization
CompaniesMarketCap · market data
Market-cap reference for Zoetis, including June 2026 market capitalization and June 26, 2026 end-of-day market-cap comparison.
Reviewed 2026-06-27
Zoetis Statistics and Valuation
StockAnalysis · market data
Market-data source for trailing P/E ratio, market capitalization cross-check, shares outstanding, revenue, net income, and price timestamp.
Reviewed 2026-06-27